Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 for CD4 Lymphopenia in High Grade Glioma
NCT02659800Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2018
- Primary completion
- Mar 2022
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efineptakin alfa in lymphopenia (5 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Absolute total CD4 cell counts at 6 weeks. Started Oct 2018; status: terminated.
02
Drugs
efineptakin alfa
03
Conditions
lymphopenia
Beyond the preview
Go deeper on NCT02659800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659800.